Coverage
-
January 29, 2024
Federal prosecutors in Pennsylvania dropped insider trading charges against a former executive of the since-merged pharmaceutical company Mylan just weeks before trial due to what defense attorneys said was flimsy evidence against their client.
2 other articles on this case.
View all »